1.
Wełnicki M. Why we choose fenofibrate? Fenofibrate in long-term therapy – larger packages, greater benefits for patients with atherogenic dyslipidemia. J EBM [Internet]. 2025Jun.30 [cited 2026Nov.22];18(2(67):290-2. Available from: https://www.journalsmededu.pl/index.php/jebm/article/view/3385